logo
logo

Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

Jun 10, 2020•about 5 years ago

Amount Raised

$85 Million

Round Type

series c

Cambridge

Description

Checkmate Pharmaceuticals (Checkmate), a clinical stage biotechnology company focused on improving patients’ lives with its novel approach to cancer immunotherapy, announced that it has completed an $85 million Series C financing. Checkmate plans to use the proceeds from the financing to support the continued clinical development of CMP-001 in anti-PD-1 refractory melanoma as well as to pursue studies in additional indications, such as front-line melanoma and head and neck squamous cell carcinoma.

Company Information

Company

Checkmate Pharmaceuticals

Location

Cambridge, Maryland, United States

About

Checkmate Pharmaceuticals is a clinical stage biotechnology company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells in combination with other therapies. The company is leveraging its expertise and the vast body of knowledge in the field of CpG oligonucleotides to validate an approach designed to combine the ability of CpG DNA to activate an anti-tumor T cell response with checkpoint inhibition to overcome a tumor’s ability to mute the immune response. Checkmate is a privately held company headquartered in Cambridge, MA. Information regarding Checkmate is available at www.checkmatepharma.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People